Description
| Description | SCH-23390 maleate (R-(+)-SCH-23390 maleate) is a potent and selective antagonist of dopamine D1-like receptor (1 and D5 receptor with Kis of 0.2 nM and 0.3 nM, respectively). |
| Targets&IC50 | D5:0.3 nM (Ki), D1:0.2 nM (Ki), GIRK:268 nM, 5-HT2C:9.3 nM (Ki) |
| In vitro | SCH-23390 could reverse the Isosibiricin-mediated inhibition of the NLRP3/caspase-1 inflammasome pathway[4].SCH-23390 (1 μM) treatment reverses the inhibitory effects of Isosibiricin on NLRP3 expression and the cleavages of caspase-1 and IL-1β in the LPS-induced BV-2 cells. |
| In vivo | SCH-23390 can eliminate systemic seizures caused by chemical convulsions:pilocarpine and soman. SCH-23390 has also been used in studies of other neurological disorders in which the dopamine system has been implicated(psychosis and Parkinson’s disease). Apart from the study of neurological disorders, SCH-23390 has been wildly used as a tool in the topographical determination of brain D1 receptors in rodents, nonhuman primates, and humans[1]. SCH-23390 is a very short-acting compound with an elimination half-life of around 25 min following administration of 0.3 mg/kg i.p. in the rat[1]. SCH-23390 augments dopamine-induced ductus constriction in CD-1 mouse vessels under newborn O2 conditions[5]. |
| Synonyms | R-(+)-SCH-23390 maleate |
| Molecular Weight |
403.86 |
| Formula | C21H22ClNO5 |
| CAS No. | 87134-87-0 |
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
